Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 7/20 | 0.61 |
| ▸ | WDR5 | P61964 | 7/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19638228 | 0.85 | MYC (0.44) | MYCWDR5ALDH1A1CDC7DBF4 | |
| SCHEMBL28724215 | 0.83 | MYC (0.61) | MYCWDR5ADORA2AADORA1ERBB2 | |
| SCHEMBL1849138 | 0.83 | MYC (0.43) | MYCWDR5ADORA2AADORA1ALDH1A1 | |
| SCHEMBL1449744 | 0.83 | CDC7 (0.58) | ADORA2AADORA1ALDH1A1CDC7DBF4 | |
| SCHEMBL31311375 | 0.83 | MPL (0.47) | MYCWDR5ADORA1ALDH1A1CDC7 | |
| SCHEMBL1850391 | 0.83 | MPL (0.47) | MYCWDR5ADORA1ALDH1A1CDC7 | |
| SCHEMBL30309309 | 0.81 | ADORA1 (0.55) | MYCWDR5ADORA2AADORA1CHUK | |
| SCHEMBL1848775 | 0.81 | ADORA1 (0.55) | MYCWDR5ADORA2AADORA1CHUK | |
| SCHEMBL1853759 | 0.81 | CDC7 (0.60) | MYCWDR5ADORA2AADORA1ALDH1A1 | |
| SCHEMBL29765496 | 0.81 | MYC (0.41) | MYCWDR5ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2026-04-16 | — | — | US | disclosed |
| EP-4637734-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARy AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250051321-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2025004567-A1 | ORGANIC ELECTRONIC ELEMENT AND COMPOUND | 東ソー株式会社 | 2025-01-02 | — | — | WO | disclosed |
| EP-4438601-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Jemincare Pharmaceutical Co., Ltd. (CN) | 2024-10-02 | — | — | EP | disclosed |
| CN-115916777-B | ATX inhibitor and preparation method and application thereof | 苏州爱科百发生物医药技术有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118317958-A | Tri-fused ring derivative and preparation method and application thereof | 上海济煜医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024134227-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARY AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2024-06-27 | — | — | WO | disclosed |
| CN-113874354-B | Pyridone derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20140303140-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014139882-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139882-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-09-18 | — | — | WO | disclosed |
| CN-101835766-B | As adenosine A1Receptor antagonist compounds | PALOBIOFARMA SL | 2013-09-25 | — | — | CN | disclosed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | disclosed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
| CN-101835766-A | As adenosine A1Novel compounds of receptor antagonists | PALOBIOFARMA SL | 2010-09-15 | — | — | CN | disclosed |
| EP-2197860-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044250-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051321-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | HABP2, NOTUM, SENP8 | MYC 4067/4885WDR5 3644/4885ADORA2A 4213/4885 |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATXN10, GCG, ATXN2L | MYC 2349/4885WDR5 2912/4885ADORA2A 3423/4885 |
| US-20140303140-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | MYC 4356/4885WDR5 1840/4885ADORA2A 401/4885 |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | MYC 3683/4885WDR5 4002/4885ADORA2A 2/4885 |
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | PPARG, FABP1, PPARA | MYC 449/4885WDR5 3362/4885ADORA2A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.